Effect of Epigallocatechin-gallate on Inner Retinal Function in Ocular Hypertension and Glaucoma: a Short-term Study by Pattern Electroretinogram

Overview

Journal Graefes Arch Clin Exp Ophthalmol

Specialty Ophthalmology

Date 2009 Mar 18

PMID 19290537

Citations 22

Authors

Benedetto Falsini

Dario Marangoni

Tommaso Salgarello

Giovanna Stifano

Lucrezia Montrone

Salvatore Di Landro

Laura Guccione

Emilio Balestrazzi

Alberto Colotto

Affiliations

Soon will be listed here.

Abstract

Background: Epigallocatechin-gallate (EGCG) is a powerful antioxidant with suggested neuroprotective action. The aim of this study was to evaluate the effect of short-term supplementation of EGCG on inner retinal function in ocular hypertension (OHT) and open-angle glaucoma (OAG).

Methods: Eighteen OHT and 18 OAG patients (perimetric mean deviation: >-10 dB) were randomly assigned to assume oral placebo or EGCG over a 3-month period in a randomized, placebo-controlled, double-blind, cross-over design clinical trial (clinicaltrials.gov identifier: NCT00476138). Pattern-evoked electroretinograms (PERGs) to 1.6 cycles/degree square-wave gratings, counterphased at 16 reversals/second, and standard automated perimetry (Humphrey 30-2) were assessed at the study entry (baseline), and after 3 months of placebo or EGCG.

Results: After EGCG, PERGs of OAG, but not OHT patients were increased in amplitude, compared either to baseline values (mean amplitude change: 0.06 log microV, p < 0.05) or to PERG amplitude values found in the same patients after placebo administration (mean change: -0.02 log microV, p not significant; difference between EGCG and placebo: 0.08 log microV, p < 0.05). In both OHT and OAG patients, standard automated perimetry did not show significant changes after either EGCG or placebo. In individual OAG patients, the magnitude of PERG amplitude increment after EGCG was inversely related (r = -0.8, p < 0.01) to corresponding baseline amplitudes.

Conclusions: Although this study cannot provide evidence for long-term benefit of EGCG supplementation in OAG, and the observed effect is small, the results suggest that EGCG might favourably influence inner retinal function in eyes with early to moderately advanced glaucomatous damage.

Citing Articles

Health Benefits of Epigallocatechin Gallate and Forskolin with a Special Emphasis on Glaucoma and Other Retinal Diseases.

Rusciano D Medicina (Kaunas). 2025; 60(12.

PMID: 39768839 PMC: 11678229. DOI: 10.3390/medicina60121957.

Potential therapeutic effects of green tea () in eye diseases, a review.

Boroughani M, Tahmasbi Z, Heidari M, Johari M, Hashempur M, Heydari M Heliyon. 2024; 10(7):e28829.

PMID: 38601618 PMC: 11004586. DOI: 10.1016/j.heliyon.2024.e28829.

Pharmaceutical Approaches to Normal Tension Glaucoma.

Salvetat M, Pellegrini F, Spadea L, Salati C, Zeppieri M Pharmaceuticals (Basel). 2023; 16(8).

PMID: 37631087 PMC: 10458083. DOI: 10.3390/ph16081172.

Green Tea Catechins as Therapeutic Antioxidants for Glaucoma Treatment.

Ng T, Chu K, Wang C, Pang C Antioxidants (Basel). 2023; 12(7).

PMID: 37507860 PMC: 10376590. DOI: 10.3390/antiox12071320.

Therapeutic Activity of Green Tea Epigallocatechin-3-Gallate on Metabolic Diseases and Non-Alcoholic Fatty Liver Diseases: The Current Updates.

James A, Wang K, Wang Y Nutrients. 2023; 15(13).

PMID: 37447347 PMC: 10346988. DOI: 10.3390/nu15133022.

References

Fredette M, Anderson D, Porciatti V, Feuer W . Reproducibility of pattern electroretinogram in glaucoma patients with a range of severity of disease with the new glaucoma paradigm. Ophthalmology. 2007; 115(6):957-63. PMC: 2710310. DOI: 10.1016/j.ophtha.2007.08.023. View

Falsini B, Marangoni D, Salgarello T, Stifano G, Montrone L, Campagna F . Structure-function relationship in ocular hypertension and glaucoma: interindividual and interocular analysis by OCT and pattern ERG. Graefes Arch Clin Exp Ophthalmol. 2008; 246(8):1153-62. DOI: 10.1007/s00417-008-0808-5. View

Mandel S, Avramovich-Tirosh Y, Reznichenko L, Zheng H, Weinreb O, Amit T . Multifunctional activities of green tea catechins in neuroprotection. Modulation of cell survival genes, iron-dependent oxidative stress and PKC signaling pathway. Neurosignals. 2005; 14(1-2):46-60. DOI: 10.1159/000085385. View

Colotto A, Falsini B, Salgarello T, Iarossi G, Galan M, SCULLICA L . Photopic negative response of the human ERG: losses associated with glaucomatous damage. Invest Ophthalmol Vis Sci. 2000; 41(8):2205-11. View

Riva C, Salgarello T, Logean E, Colotto A, Galan E, Falsini B . Flicker-evoked response measured at the optic disc rim is reduced in ocular hypertension and early glaucoma. Invest Ophthalmol Vis Sci. 2004; 45(10):3662-8. DOI: 10.1167/iovs.04-0100. View

Colotto A, Salgarello T, Giudiceandrea A, De Luca L, Coppe A, Buzzonetti L . Pattern electroretinogram in treated ocular hypertension: a cross-sectional study after timolol maleate therapy. Ophthalmic Res. 1995; 27(3):168-77. DOI: 10.1159/000267663. View

Hayreh S . The role of age and cardiovascular disease in glaucomatous optic neuropathy. Surv Ophthalmol. 1999; 43 Suppl 1:S27-42. DOI: 10.1016/s0039-6257(99)00018-1. View

Weinreb R . Glaucoma neuroprotection: What is it? Why is it needed?. Can J Ophthalmol. 2007; 42(3):396-8. DOI: 10.3129/can j ophthalmol.i07-045. View

Tedeschi E, Suzuki H, Menegazzi M . Antiinflammatory action of EGCG, the main component of green tea, through STAT-1 inhibition. Ann N Y Acad Sci. 2002; 973:435-7. DOI: 10.1111/j.1749-6632.2002.tb04678.x. View

10.

Flammer J, Orgul S . Optic nerve blood-flow abnormalities in glaucoma. Prog Retin Eye Res. 1998; 17(2):267-89. DOI: 10.1016/s1350-9462(97)00006-2. View

11.

Osborne N, Chidlow G, Nash M, Wood J . The potential of neuroprotection in glaucoma treatment. Curr Opin Ophthalmol. 1999; 10(2):82-92. DOI: 10.1097/00055735-199904000-00002. View

12.

Viswanathan S, Frishman L, Robson J, Walters J . The photopic negative response of the flash electroretinogram in primary open angle glaucoma. Invest Ophthalmol Vis Sci. 2001; 42(2):514-22. View

13.

Cabrera C, Artacho R, Gimenez R . Beneficial effects of green tea--a review. J Am Coll Nutr. 2006; 25(2):79-99. DOI: 10.1080/07315724.2006.10719518. View

14.

Bach M . Electrophysiological approaches for early detection of glaucoma. Eur J Ophthalmol. 2001; 11 Suppl 2:S41-9. DOI: 10.1177/112067210101102s05. View

15.

Wiggs J . Genetic etiologies of glaucoma. Arch Ophthalmol. 2007; 125(1):30-7. DOI: 10.1001/archopht.125.1.30. View

16.

Zhang B, Rusciano D, Osborne N . Orally administered epigallocatechin gallate attenuates retinal neuronal death in vivo and light-induced apoptosis in vitro. Brain Res. 2008; 1198:141-52. DOI: 10.1016/j.brainres.2007.12.015. View

17.

Chauhan B, Garway-Heath D, Goni F, Rossetti L, Bengtsson B, Viswanathan A . Practical recommendations for measuring rates of visual field change in glaucoma. Br J Ophthalmol. 2008; 92(4):569-73. PMC: 2564806. DOI: 10.1136/bjo.2007.135012. View

18.

Mandel S, Weinreb O, Amit T, Youdim M . Cell signaling pathways in the neuroprotective actions of the green tea polyphenol (-)-epigallocatechin-3-gallate: implications for neurodegenerative diseases. J Neurochem. 2004; 88(6):1555-69. DOI: 10.1046/j.1471-4159.2003.02291.x. View

19.

Chow H, Cai Y, Alberts D, Hakim I, Dorr R, Shahi F . Phase I pharmacokinetic study of tea polyphenols following single-dose administration of epigallocatechin gallate and polyphenon E. Cancer Epidemiol Biomarkers Prev. 2001; 10(1):53-8. View

20.

Lorenz M, Wessler S, Follmann E, Michaelis W, Dusterhoft T, Baumann G . A constituent of green tea, epigallocatechin-3-gallate, activates endothelial nitric oxide synthase by a phosphatidylinositol-3-OH-kinase-, cAMP-dependent protein kinase-, and Akt-dependent pathway and leads to endothelial-dependent vasorelaxation. J Biol Chem. 2003; 279(7):6190-5. DOI: 10.1074/jbc.M309114200. View